Cassandra J. Schmitt, PharmD, determines risk factors associated with severe COVID-19 disease progression, discusses efficacy and safety outcomes of novel agents for the outpatient treatment of COVID-19, identifies the ideal candidate to receive treatment with oral molnupiravir, nirmatrelvir/ritonavir, or intravenous monoclonal antibodies for mild-to-moderate COVID-19.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.